Anti-Fibrinolytic Drugs - Norway

Norway

In Norway, the revenue in the Anti-Fibrinolytic Drugs market is projected to reach US$53.24m in 2024.
It is expected to show an annual growth rate (CAGR 2024-2029) of 3.80%, resulting in a market volume of US$64.16m by 2029.
When compared globally, United States is forecasted to generate the highest revenue of US$9,858.00m in 2024.
Norway is experiencing a growing demand for anti-fibrinolytic drugs, driven by an aging population and increasing prevalence of cardiovascular diseases.

Key regions: United Kingdom, Brazil, Europe, France, Canada

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for Anti-Fibrinolytic Drugs in Norway has been steadily increasing in recent years.

Customer preferences: Norwegian customers have shown a preference for Anti-Fibrinolytic Drugs due to their effectiveness in treating bleeding disorders. Patients suffering from conditions such as hemophilia and von Willebrand disease have benefited greatly from these drugs. Additionally, the drugs have been used in surgeries to prevent excessive bleeding.

Trends in the market: The market for Anti-Fibrinolytic Drugs in Norway has been growing due to an increase in the number of patients suffering from bleeding disorders. The aging population has also contributed to the growth of the market as older individuals are more prone to bleeding disorders. Another trend in the market is the development of new drugs that are more effective and have fewer side effects.

Local special circumstances: Norway has a well-developed healthcare system that provides universal coverage to its citizens. This has made it easier for patients to access Anti-Fibrinolytic Drugs. Additionally, the Norwegian government has been investing in healthcare infrastructure, which has contributed to the growth of the market.

Underlying macroeconomic factors: The Norwegian economy has been growing steadily in recent years, which has led to an increase in healthcare spending. This has made it easier for patients to access Anti-Fibrinolytic Drugs. Additionally, the government has been investing in research and development, which has led to the development of new and more effective drugs. The favorable regulatory environment has also contributed to the growth of the market as it has made it easier for pharmaceutical companies to bring new drugs to market.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.